Phase I Adjuvant Trial of Sorafenib in Hepatocellular Carcinoma Patients After Liver Transplantation.

Trial Profile

Phase I Adjuvant Trial of Sorafenib in Hepatocellular Carcinoma Patients After Liver Transplantation.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 May 2013

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 18 May 2011 New source identified and integrated (University of Southern California Norris Comprehensive Cancer Center).
    • 30 Sep 2010 Additional lead trial investigator (Edward Lin) identified as reported by ClinicalTrials.gov. (NCT00844168)
    • 21 Sep 2010 Planned end date changed from Jan 2014 to Jan 2015 as reported by ClinicalTrials.gov (NCT00844168).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top